There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy for chronic obstructive pulmonary disease (COPD), according to real-world ...

The FDA approved United Kingdom-based GlaxoSmithKline’s Trelegy Ellipta, a once-daily inhaler that contains three medicines for chronic obstructive pulmonary disease. The inhaler, developed with the ...

Those receiving budesonide-glycopyrrolate-formoterol compared with fluticasone-umeclidinium-vilanterol had a higher risk for a first moderate COPD exacerbation. William B. Feldman, MD, MPH, from ...

The Institute for Clinical and Economic Review (ICER) released a report on Monday assessing the clinical effectiveness and value of GSK Plc's (NYSE:GSK) chronic obstructive pulmonary disease (COPD) ...

(HealthDay News) — For patients with chronic obstructive pulmonary disease (COPD), once-daily single-inhaler triple therapy is better for lung function and health-related quality of life than inhaled ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the world’s first low-carbon version of a triple-combination inhaler for chronic obstructive pulmonary disease (COPD). The ...

Qualcomm Life and Boehringer Ingelheim have announced that they will work together to develop the next generation of Boehringer's Respimat connected inhaler. Propeller Health, which developed the ...

The researchers evaluated budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol in preventing COPD exacerbations and pneumonia hospitalizations in real-world settings. They ...

AeroRx Therapeutics, Inc., a clinical-stage biopharmaceutical company developing proprietary nebulized combination therapies for chronic respiratory diseases, today announced the closing of a $21 ...

GLOUCESTER — In April alone, Leatrice Croswell was hospitalized three times for severe shortness of breath linked to his chronic obstructive pulmonary disease, or COPD. By then, Croswell, a ...